PLX - AMEX
Protalix BioTherapeutics, Inc.
$2.01
+1.8%Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.
At a Glance
Live SnapshotProtalix BioTherapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Significant working capital drain. Growth may be consuming cash through inventory buildup or receivables extension—monitor closely.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Protalix BioTherapeutics, Inc. Cash Flow Statement
PLX • AMEX
| Protalix BioTherapeutics, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||||||||
-6.6M | 2.9M | 8.3M | -14.9M | -27.6M | -6.5M | -18.3M | -26.5M | -85.3M | -29.2M | -27.3M | -29.9M | -27.8M | -11.6M | -36.5M | -29M | -31.4M | -22.4M | -22.5M | -9.4M | |
0.0 | 1.3M | 1.2M | 1.1M | 1.1M | 1.3M | 1.6M | 1.7M | 1.9M | 2M | 2.4M | 3.1M | 3.5M | 3.7M | 3.6M | 3.1M | 2M | 1.3M | 759K | 502K | |
0.0 | 236K | -3.1M | 0.0 | 0.0 | 0.0 | -68K | -64K | 39.4M | -7.6M | 1.6M | 115K | 142K | 240K | 36.9M | -617K | -218K | -3M | -11.7M | -3.5M | |
0.0 | 3.3M | 3.4M | 2.1M | 2.4M | 3.1M | 835K | 514K | 337K | 988K | 1.8M | 1.2M | 4.1M | 7.8M | 886K | 1.3M | 2.7M | 3.1M | 10.8M | 3.4M | |
4.7M | 138K | -638K | -1.2M | 3.9M | 3.1M | 3.4M | 3.1M | 4.6M | 581K | 569K | 1.9M | -137K | -171K | -36.4M | 377K | 265K | 3M | 11.1M | 3.6M | |
-10.1M | 811K | -10.5M | -12M | 9.9M | -27.1M | -6.8M | 13.5M | 29.1M | 1.1M | -3.3M | -5.7M | -10.5M | 741K | 7.9M | -13.6M | 71.2M | 2M | 1M | 269K | |
-12M | 8.7M | -1.3M | -25M | -10.3M | -26.1M | -19.4M | -7.7M | -10M | -32.1M | -24.3M | -29.3M | -30.7M | 635K | -23.6M | -38.5M | 44.5M | -16M | -10.4M | -5.1M | |
INVESTING ACTIVITIES | ||||||||||||||||||||
(0.0) | -1.3M | -1.1M | -628K | -1.5M | -655K | -627K | -686K | -971K | -849K | -464K | -785K | -1.9M | -2.1M | -5.7M | -7.9M | -6.2M | -3.4M | -2.3M | -842K | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (3K) | (20K) | (3K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
(0.0) | -15M | -20.4M | -16M | -37.8M | -20M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -90K | -212K | -218K | -165K | -137K | (0.0) | (0.0) | (0.0) | -47K | |
0.0 | 20.4M | 5M | 11M | 57.8M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-2.4M | 83K | -142K | 593K | 380K | 703K | -256K | 95K | -148K | -118K | 39.9M | -126K | -212K | -218K | 2K | -137K | 21K | -330K | -103K | -91K | |
-2.4M | (4.2M) | -16.7M | -5M | (18.9M) | -20M | -883K | -591K | -1.1M | -967K | (39.4M) | -1M | -2.1M | -2.3M | -5.9M | -8M | -6.2M | -3.7M | -2.4M | -980K | |
FINANCING ACTIVITIES | ||||||||||||||||||||
9.3M | 3.6M | 24M | 8.2M | 46.2M | 46.2M | 0.0 | 0.0 | 0.0 | 0.0 | 6.1M | 0.0 | 0.0 | 25.3M | 20.7M | 0.0 | 0.0 | -56K | 58.7M | 16.4M | |
0.0 | -20.4M | 0.0 | 0.0 | -34.1M | -215K | 0.0 | -4.8M | -1.4M | 19.7M | 0.0 | 0.0 | 66.8M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -56K | (0.0) | (0.0) | |
0.0 | 0.0 | 712K | 2K | 0.0 | 472K | 0.0 | 0.0 | 0.0 | 14K | 534K | 46K | 112K | 1.2M | 277K | 501K | 293K | -56K | -104K | 341K | |
9.3M | -16.8M | 24.7M | 8.2M | 12.1M | 46.5M | 0.0 | -4.8M | -1.4M | 19.7M | 6.6M | 46K | 66.9M | 26.6M | 20.9M | 501K | 293K | -51K | 58.6M | 16.7M | |
CASH FLOW SUMMARY | ||||||||||||||||||||
655K | 25K | -114K | -77K | 6K | 64K | 225K | -270K | 414K | 277K | -131K | -1.4M | 226K | 127K | -388K | 589K | 99K | 550K | 756K | 0.0 | |
-4.4M | -3.9M | 6.5M | -21.9M | 20.7M | 473K | -20M | -13.4M | -12.1M | -13.1M | 21.6M | -31.6M | 34.4M | 25M | -8.9M | -45.4M | 38.7M | -19.2M | 46.4M | 10.6M | |
19.8M | 23.6M | 17.1M | 39M | 18.3M | 17.8M | 37.8M | 51.2M | 63.3M | 76.4M | 54.8M | 86.4M | 52M | 27M | 35.9M | 81.3M | 42.6M | 61.8M | 15.4M | 4.7M | |
15.4M | 19.8M | 23.6M | 17.1M | 39M | 18.3M | 17.8M | 37.8M | 51.2M | 63.3M | 76.4M | 54.8M | 86.4M | 52M | 27M | 35.9M | 81.3M | 42.6M | 61.8M | 15.4M | |
-13.6M | 7.4M | -2.5M | -25.6M | -11.7M | -26.8M | -20M | -8.4M | -11M | -32.9M | -24.7M | -30.1M | -32.5M | -1.4M | -29.3M | -46.3M | 38.3M | -19.4M | -12.8M | -5.9M |
SEC Filings
PLX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 21, 2026 | May 21, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 13, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 13, 2026 | May 13, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 30, 2026 | June 25, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 18, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 18, 2026 | March 18, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 09, 2026 | March 09, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 11, 2026 | February 11, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 30, 2026 | January 30, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 05, 2026 | January 05, 2026 | 2026 |
Related Guides
Continue your PLX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.